Conducting A Drug Development Orchestra To Treat Mental Illness

By Ben Comer, Chief Editor, Life Science Leader

For people living with schizophrenia, the current drug treatment landscape is filled with cracks, crevices, and canyons that prevent a majority of patients from reaching anything close to a normal life. Lifelong chronic disability with acute episodes of psychosis continues to be the most common health outcome, with schizophrenia patients dying, on average, 30 years sooner than healthy individuals matched demographically by age and ethnicity. Only 10% of schizophrenia patients are ever gainfully employed in their lifetimes.